Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study.

The 300 mg group showed a trend toward lower nasal symptom scores and lower daily medication scores (dMS) during the pollen season relative to the 150 mg group; however, these differences did not reach statistical significance.

also in 53,322 other papers